In conclusion, the present study showed the prevalence of aspirin resistance is 0.6% and the prevalence of aspirin semi-responsiveness is 12.7%. The risk factor for aspirin resistance is older age. No association between duration and aspirin dosage with aspirin resistance. However, aspirin resistance in the laboratory testing may be associated with increased atherothrombosis. Presently, there is not enough evidence showing that increase aspirin dosage or switching to another antiplatelet with different mechanism have clinical benefit. These options should be based on clinical judgement.